Back to Search Start Over

Targeting progesterone signaling prevents metastatic ovarian cancer.

Authors :
Kim, Olga
Eun Young Park
Sun Young Kwon
Sojin Shin
Emerson, Robert E.
Yong-Hyun Shin
DeMayo, Francesco J.
Lydon, John P.
Coffey, Donna M.
Hawkins, Shannon M.
Quilliam, Lawrence A.
Dong-Joo Cheon
Fernández, Facundo M.
Nephew, Kenneth P.
Karpf, Adam R.
Widschwendter, Martin
Sood, Anil K.
Bast Jr, Robert C.
Godwin, Andrew K.
Miller, Kathy D.
Source :
Proceedings of the National Academy of Sciences of the United States of America; 12/15/2020, Vol. 117 Issue 50, p31993-32004, 12p
Publication Year :
2020

Abstract

Effective cancer prevention requires the discovery and intervention of a factor critical to cancer development. Here we show that ovarian progesterone is a crucial endogenous factor inducing the development of primary tumors progressing to metastatic ovarian cancer in a mouse model of high-grade serous carcinoma (HGSC), the most common and deadliest ovarian cancer type. Blocking progesterone signaling by the pharmacologic inhibitor mifepristone or by genetic deletion of the progesterone receptor (PR) effectively suppressed HGSC development and its peritoneal metastases. Strikingly, mifepristone treatment profoundly improved mouse survival (~18 human years). Hence, targeting progesterone/PR signaling could offer an effective chemopreventive strategy, particularly in high-risk populations of women carrying a deleterious mutation in the BRCA gene. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00278424
Volume :
117
Issue :
50
Database :
Complementary Index
Journal :
Proceedings of the National Academy of Sciences of the United States of America
Publication Type :
Academic Journal
Accession number :
147672601
Full Text :
https://doi.org/10.1073/pnas.2013595117